Table 3.
Variable | RS | FP1 | FP2 | FP3 | FP4 |
---|---|---|---|---|---|
Diabetic retinopathy | |||||
Absent (%) | 231 (58.2) | 289 (72.8) | 278 (70) | 234 (58.9) | 280 (70.5) |
Present (%) | 166 (41.8) | 108 (27.2) | 119 (30) | 163 (41.1) | 117 (29.5) |
Kappa (95% CI) | 0.56 (0.48; 0.64) | 0.69 (0.61; 0.76) | 0.73 (0.66; 0.80) | 0.71 (0.64; 0.78) | |
Sensitivity (95% CI) | 58.2 (50.3; 65.8) | 68.5 (60.8; 75.5) | 83.6 (77.1; 88.9) | 69.1 (61.4; 76) | |
Specificity (95% CI) | 94.8 (91.1; 97.3) | 97.4 (94.5; 99) | 89.2 (84.5; 92.9) | 98.7 (96.3; 99.7) | |
PPV (95% CI) | 88.9 (81.4; 94.1) | 95 (89.3; 98.1) | 84.7 (78.2; 89.8) | 97.4 (92.7; 99.5) | |
PNV (95% CI) | 76.1 (70.8; 80.9) | 81.3 (76.2; 85.7) | 88.5 (83.7; 92.3) | 81.8 (76.8; 86.1) | |
Severity | |||||
Absent (%) | 231 (58.2) | 289 (72.8) | 278 (70) | 234 (58.9) | 280 (70.5) |
Treated (%) | 15 (3.8) | 15 (3.8) | 14 (3.5) | 20 (5) | 14 (3.5) |
Non-proliferative (%) | 143 (36) | 72 (18.1) | 100 (25.2) | 132 (33.2) | 66 (16.6) |
Proliferative (%) | 8 (2) | 21 (5.3) | 5 (1.3) | 9 (2.3) | 37 (9.3) |
Non-gradable (%) | 0 (0) | 0 (0) | 0 (0) | 2 (0.5) | 0 (0.0) |
Weighted kappa (95% CI) | 0.51 (0.44; 0.59) | 0.66 (0.59; 0.73) | 0.69 (0.62; 0.76) | 0.64 (0.58; 0.71) | |
Macular edema | |||||
Absent (%) | 309 (77.8) | 363 (91.4) | 362 (91.2) | 358 (90.2) | 343 (86.4) |
Present (%) | 88 (22.2) | 34 (8.6) | 35 (8.8) | 39 (9.8) | 54 (13.6) |
Kappa (95% CI) | 0.33 (0.21; 0.44) | 0.39 (0.28; 0.51) | 0.37 (0.26; 0.48) | 0.51 (0.40; 0.62) | |
Sensitivity (95% CI) | 28.4 (19.3; 39) | 33 (23.3; 43.8) | 33 (23.3; 43.8) | 47.7 (37; 58.6) | |
Specificity (95% CI) | 97.1 (94.5; 98.7) | 98.1 (95.8; 99.3) | 96.8 (94.1; 98.4) | 96.1 (93.3; 98) | |
PPV (IC 95%) | 73.5 (55.6; 87.1) | 82.9 (66.4; 93.4) | 74.4 (57.9; 87) | 77.8 (64.4; 88) | |
PNV (IC 95%) | 82.6 (78.3; 86.4) | 83.7 (79.5; 87.4) | 83.5 (79.3; 87.2) | 86.6 (82.5; 90) |
CI, confidence interval; PPV, predictive positive value; PNV, predictive negative value.